SSRIs may pack more punch at the cellular level than believed

Aug 16, 2010

A new discovery about selective serotonin reuptake inhibitors (SSRIs) suggests that these drugs, which are used to treat mental health disorders like depression and anxiety, have multiple effects on our cells. In a research report published in the August 2010 issue of GENETICS, researchers used yeast cells to identify secondary drug targets or pathways affected by SSRIs. Such secondary pathways could help explain why different people taking the same drug may experience different effects, and could also lead to new types of drugs altogether.

"We hope that our study begins to illuminate the full breadth of pharmacological effects of antidepressants on cellular physiology starting with the simple unicellular eukaryote, budding yeast," said Ethan O. Perlstein, Ph.D, a researcher involved in the work from the Lewis-Sigler Institute for Integrative Genomics at Princeton University in New Jersey. "Furthermore, our work validates the notion that simple model organisms may be useful for the study of complex human disease."

Knowing that a high concentration of sertraline (Zoloft®) is toxic to , scientists applied a lethal dose to millions of these cells and fished out a few cells that became resistant to the drug. Researchers then identified the underlying mutations in those cells and applied genetic, biochemical, and electron microscopic imaging techniques to characterize the molecular basis of resistance. Their results suggest that SSRIs may actually affect more than one process in a cell, including non-protein targets such as phospholipid membranes. Additionally, the study's results demonstrate that sertraline targets intracellular membranes and modulate pathways involved in vesicle trafficking that are present in both yeast and human . Vesicle trafficking plays an important role in how neural synapses develop and function. More work is necessary, however, to determine the exact clinical relevance of this secondary .

"There's no question that SSRIs help thousands of people with mental health problems," said Mark Johnston, Editor-in-Chief of the journal GENETICS, "but as this research shows, there is still some mystery about how they help us. This study a key first-step toward giving us a comprehensive answer to how SSRI's work, and it may open doors to entirely new therapies."

Explore further: Epigenetic driver of glioblastoma provides new therapeutic target

More information: www.genetics.org

Related Stories

Autism: Lack of evidence for antidepressants

Aug 07, 2010

Antidepressants commonly prescribed to people with autistic spectrum disorders cannot be recommended based on current evidence, a new study by Cochrane Researchers concludes. Despite some evidence of benefits in adults diagnosed ...

Serotonin Made in Breast Cancer Cells, Researchers Show

Nov 24, 2009

(PhysOrg.com) -- Researchers at the University of Cincinnati have documented that the brain hormone serotonin is made in human breast cancer cells and functions abnormally, contributing to malignant growth.

Recommended for you

Extra DNA acts as a 'spare tire' for our genomes

Jul 06, 2015

Carrying around a spare tire is a good thing—you never know when you'll get a flat. Turns out we're all carrying around "spare tires" in our genomes, too. Today, in ACS Central Science, researchers report that an extra ...

Genetic testing in kids is fraught with complications

Jul 02, 2015

A woman coping with the burden of familial breast cancer can't help but wonder if her young daughter will suffer the same fate. Has she inherited the same disease-causing mutation? Is it best to be prepared ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.